Product Code: GMDHC7389IDB
Summary
Global Markets Direct's, 'General Anxiety Disorder - Pipeline Review, H2 2015', provides an overview of the General Anxiety Disorder's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for General Anxiety Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for General Anxiety Disorder and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of General Anxiety Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for General Anxiety Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the General Anxiety Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- General Anxiety Disorder Overview
- Therapeutics Development
- Pipeline Products for General Anxiety Disorder - Overview
- Pipeline Products for General Anxiety Disorder - Comparative Analysis
- General Anxiety Disorder - Therapeutics under Development by Companies
- General Anxiety Disorder - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- General Anxiety Disorder - Products under Development by Companies
- General Anxiety Disorder - Companies Involved in Therapeutics Development
- Bionomics Limited
- Edgemont Pharmaceuticals, LLC
- H. Lundbeck A/S
- General Anxiety Disorder - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- BHV-0223 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BNC-210 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- lorazepam ER - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tedatioxetine hydrobromide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- vortioxetine hydrobromide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- General Anxiety Disorder - Recent Pipeline Updates
- General Anxiety Disorder - Dormant Projects
- General Anxiety Disorder - Discontinued Products
- General Anxiety Disorder - Product Development Milestones
- Featured News & Press Releases
- Oct 06, 2015: Portage's Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223
- Sep 21, 2015: Portage's Biohaven Completes Single Dose Phase of Pharmacokinetic Trial with BHV-0223
- Aug 24, 2015: Portage's Biohaven's lead drug candidate clears FDA Investigational New Drug Application review and clinical studies to begin
- Jul 23, 2015: Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development for General Anxiety Disorder, H2 2015
- Number of Products under Development for General Anxiety Disorder - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Comparative Analysis by Late Stage Development, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- General Anxiety Disorder - Pipeline by Bionomics Limited, H2 2015
- General Anxiety Disorder - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2015
- General Anxiety Disorder - Pipeline by H. Lundbeck A/S, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- General Anxiety Disorder Therapeutics - Recent Pipeline Updates, H2 2015
- General Anxiety Disorder - Dormant Projects, H2 2015
- General Anxiety Disorder - Discontinued Products, H2 2015
List of Figures
- Number of Products under Development for General Anxiety Disorder, H2 2015
- Number of Products under Development for General Anxiety Disorder - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Routes of Administration, H2 2015
- Number of Products by Stage and Molecule Types, H2 2015
